Latham & Watkins Advises on Vaderis Therapeutics’ US$152 Million Series B Financing

Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, has announced the closing of a private US$152 million Series B financing and initiation of HEROIC, the company's global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT). The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX.

Latham & Watkins LLP represented Life Sciences at Goldman Sachs Alternatives in the funding round with a corporate deal team led by Bay Area partner Saad Khanani, with associates Jay Trewn and Camille N'Diaye-Muller. Advice was also provided on data privacy and cybersecurity matters by Bay Area partner Heather Deixler and London partner Calum Docherty, with associates Chad Leiper and Clarence Cheong; on intellectual property matters by San Diego counsel Robert Yeh, with associate Patrick Chew; on life sciences regulatory matters by Paris/Brussels partner Eveline Van Keymeulen and San Diego counsel Amy Speros, with associates Breanna Comunale, Luke Nauth, and Jeanne Fabre; and on tax matters by Bay Area partner Grace Lee, with associate Gregory Conyers.